Innate Pharma SA of France has appointed Marcel Rozencweig as senior vice president in charge of clinical and regulatory strategy. Dr Rozencweig is currently adjunct associate professor of medicine at New York University in New York. He is a medical doctor, having graduated from the Université Libre de Bruxelles in Belgium.
Dr Rozencweig spent many years in industry and is an expert in medical oncology and anti-cancer drug development. He built and led the clinical research group at Bristol-Myers Squibb that developed all of the new chemical entities for cancer brought by BMS to the market from 1983 to 2001 including carboplatin and paclitaxel.
Dr Rozencweig will work part-time for Innate and will be based in the US.
Copyright 2009 Evernow Publishing Ltd